Substance / Medication

Dalteparin

Overview

Active Ingredient
dalteparin
RxNorm CUI
67109

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

15 trials linked to this intervention

15
Total Trials
3
Recruiting
5
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Arce-Huamani Miguel A, Barboza Joshuan J, Martínez-Herrera José Fabián et al. · Medicina (Kaunas) · 2023
PMID: 37893585Meta-AnalysisFull text (PMC)
Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis.
Riaz Irbaz Bin, Fuentes Harry E, Naqvi Syed Arsalan Ahmed et al. · Mayo Clin Proc · 2022
PMID: 34172290Meta-Analysis
Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy.
Hellgren Margareta, Mistafa Oras · J Obstet Gynaecol · 2019
PMID: 30426808Meta-Analysis
Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer.
Cohen Alexander T, Creeper Katherine J, Alikhan Raza et al. · Thromb Haemost · 2024
PMID: 38196077RCT
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
Planquette Benjamin, Bertoletti Laurent, Charles-Nelson Anaïs et al. · Chest · 2022
PMID: 34627853RCT
Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer.
Agnelli Giancarlo, Muñoz Andrés, Franco Laura et al. · Thromb Haemost · 2022
PMID: 34530482RCT
Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study.
Ageno Walter, Vedovati Maria Cristina, Cohen Ander et al. · Thromb Haemost · 2021
PMID: 33202447RCT
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
McBane Robert D, Wysokinski Waldemar E, Le-Rademacher Jennifer G et al. · J Thromb Haemost · 2020
PMID: 31630479RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dalteparin (substance)
SNOMED CT
372563008
UMLS CUI
C0206461
RxNorm CUI
67109

Clinical Data

This intervention maps to 13 entities in the Ltrl knowledge graph.

7
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
15
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.